import
neutral
antibodi
protect
influenza
viru
well
establish
role
earli
antibodi
respons
initi
stage
infect
affect
sever
diseas
unknown
influenza
pandem
provid
uniqu
opportun
studi
patient
lack
preexist
neutral
antibodi
studi
compar
antibodi
respons
patient
sever
mild
diseas
use
sera
collect
admiss
microneutr
mn
assay
use
detect
neutral
antibodi
also
develop
enzymelink
immunosorb
assay
elisa
detect
neutral
nonneutr
antibodi
viral
antigen
splitvirion
inactiv
monoval
influenza
viru
vaccin
mn
titer
significantli
differ
two
group
p
elisa
titer
elisamn
titer
ratio
significantli
higher
patient
sever
diseas
mild
diseas
p
p
respect
find
suggest
patient
sever
diseas
larger
proport
serum
antibodi
antibodi
detect
neutral
activ
antibodi
avid
also
significantli
higher
patient
sever
diseas
mild
diseas
p
among
patient
sever
diseas
requir
posit
pressur
ventil
ppv
significantli
higher
elisa
titer
requir
ppv
p
multivari
analysi
show
elisa
titer
antibodi
avid
independ
associ
sever
diseas
higher
titer
nonneutr
antibodi
higher
avid
earli
stage
influenza
viru
infect
may
associ
wors
clinic
sever
poorer
outcom
e
pidemiolog
virolog
studi
identifi
sever
risk
factor
sever
influenza
viru
infect
includ
host
factor
extrem
age
comorbid
ill
pregnanc
obes
viral
factor
specif
viru
strain
includ
viru
viru
subtyp
specif
mutat
viral
protein
mutat
number
hemagglutinin
ha
pandem
influenza
viru
immunolog
studi
link
lower
serum
immunoglobulin
level
sever
diseas
caus
though
patient
asymptomat
develop
mild
coryz
symptom
even
multipl
risk
factor
signific
number
healthi
young
patient
develop
respiratori
failur
extrapulmonari
lifethreaten
complic
caus
therefor
unidentifi
factor
affect
progress
sever
influenza
remain
discov
earli
innat
immun
respons
influenza
viru
may
import
control
viral
replic
henc
peak
viral
load
patient
sever
diseas
admit
hospit
within
day
symptom
onset
addit
defens
factor
mount
innat
immun
system
pattern
recognit
receptor
interferonrel
antivir
mechan
complement
cascad
antimicrobi
peptid
anoth
import
immun
mechan
oper
earli
phase
infect
presenc
crossreact
antibodi
induc
prior
influenza
viru
infect
includ
preexist
crossreact
antibodi
secondari
antibodi
respons
memori
b
cell
studi
sought
assess
associ
amount
influenza
virusspecif
antibodi
earli
stage
ill
patient
outcom
furthermor
understand
contribut
nonneutr
antibodi
defin
antibodi
detect
viral
microneutr
mn
assay
use
splitvirion
inactiv
vaccin
coat
antigen
enzymelink
immunosorb
assay
elisa
avid
assay
sinc
patient
born
preexist
crossreact
neutral
antibodi
novel
viru
use
vaccin
provid
us
uniqu
opportun
investig
whether
preexist
crossreact
nonneutr
antibodi
new
viru
uniqu
role
determin
patient
outcom
rel
quantiti
influenza
virusspecif
antibodi
neutral
antibodi
analyz
compar
elisa
mn
titer
furthermor
also
compar
qualiti
antibodi
sever
mild
case
use
antibodi
avid
assay
patient
clinic
characterist
adult
patient
laboratoryconfirm
infect
avail
archiv
serum
sampl
obtain
within
day
symptom
onset
includ
exclud
group
children
year
age
patient
without
suffici
archiv
specimen
clinic
data
retriev
retrospect
review
medic
record
patient
defin
sever
diseas
requir
respiratori
support
andor
admiss
intens
care
unit
die
surviv
develop
oxygen
desatur
requir
admiss
intens
care
unit
defin
mild
diseas
studi
approv
institut
review
board
hospit
author
hong
kong
composit
vaccin
antigen
use
elisa
avid
assay
multidos
vial
vaccin
panenza
sanofi
pasteur
franc
employ
coat
antigen
elisa
vaccin
nonadjuv
splitvirion
inactiv
vaccin
accord
manufactur
dose
vaccin
contain
g
ha
batch
vaccin
use
experi
ensur
consist
elisa
elisa
method
modifi
slightli
publish
protocol
ninetysixwel
immunopl
nunc
immuno
modul
nunc
denmark
coat
l
vaccin
g
haml
nahco
ph
overnight
block
normal
goat
serum
lwell
h
wash
time
phosphatebuff
salin
contain
tween
pbst
serum
sampl
serial
dilut
ad
well
incub
h
wash
l
pb
ad
well
incub
room
temperatur
min
plate
wash
time
l
antihuman
gamma
chain
peroxidas
dilut
zymax
invitrogen
ad
well
secondari
antibodi
h
reaction
develop
ad
l
dilut
singl
solut
invitrogen
min
stop
l
n
h
optic
densiti
od
read
nm
sampl
test
duplic
mean
absorb
calcul
elisa
titer
dilut
absorb
nearest
determin
avid
elisa
perform
describ
follow
modif
first
sera
ad
dilut
expect
absorb
reach
linear
part
titrat
curv
second
sera
incub
h
urea
ad
instead
pb
concentr
urea
chosen
preliminari
experi
show
urea
concentr
alway
markedli
reduc
od
valu
even
urea
ad
incub
wash
reaction
sera
suggest
high
urea
concentr
caus
fals
low
read
remov
coat
vaccin
antigen
avid
index
defin
ratio
od
urea
od
without
urea
mn
assay
mn
assay
perform
describ
previous
briefli
serial
dilut
serum
mix
tissu
cultur
infect
dose
tcid
viru
h
ad
madindarbi
canin
kidney
cell
one
hour
infect
virusserum
mixtur
remov
serumfre
minim
essenti
medium
gml
chloromethyl
ketonetr
trypsin
tpcktrypsin
sigma
immunochem
ad
well
cytopath
effect
observ
day
incub
highest
serum
dilut
protect
cell
cytopatholog
consid
mn
titer
sampl
test
duplic
statist
analysi
mannwhitney
u
test
use
continu
variabl
wherea
chisquar
fisher
exact
test
use
categor
variabl
valu
arbitrarili
assign
mn
titer
limit
detect
ratio
elisa
mn
antibodi
titer
elisamn
titer
ratio
use
estim
quantiti
nonneutr
antibodi
statist
calcul
involv
geometr
mean
titer
gmt
perform
logtransform
titer
correl
elisa
mn
titer
assess
spearman
rank
correl
coeffici
test
stepwis
multipl
logist
regress
analysi
use
control
confound
variabl
includ
age
sex
underli
comorbid
p
valu
consid
statist
signific
total
patient
includ
studi
median
age
year
age
rang
year
twentyf
patient
femal
patient
sever
diseas
mild
diseas
tabl
signific
differ
sever
mild
diseas
group
time
interv
symptom
onset
serum
sampl
collect
p
baselin
demograph
underli
predispos
factor
patient
sever
mild
diseas
well
match
obes
analyz
bodi
mass
index
avail
patient
among
patient
sever
diseas
patient
requir
posit
pressur
ventil
ppv
respiratori
failur
admit
intens
care
unit
close
monitor
respiratori
support
patient
succumb
figur
show
comparison
antibodi
titer
patient
sever
mild
diseas
elisa
gmt
time
higher
patient
sever
diseas
mild
diseas
p
although
median
neutral
antibodi
titer
determin
mn
assay
higher
patient
sever
diseas
mild
diseas
differ
reach
statist
signific
p
elisamn
titer
ratio
significantli
higher
patient
sever
diseas
mild
diseas
p
fig
antibodi
avid
express
avid
index
significantli
higher
patient
sever
diseas
mild
diseas
p
fig
signific
correl
age
elisa
titer
mn
titer
elisamn
titer
ratio
antibodi
avid
index
among
patient
sever
diseas
requir
ppv
significantli
higher
elisa
titer
requir
ppv
trend
toward
higher
elisamn
titer
ratio
patient
requir
ppv
requir
ppv
although
differ
reach
statist
signific
tabl
multivari
analysi
adjust
sex
age
underli
comorbid
show
elisa
titer
p
avid
index
p
independ
associ
sever
diseas
humor
immun
play
import
role
host
defens
influenza
viru
infect
one
key
function
associ
protect
influenza
viru
infect
often
use
marker
success
immun
influenza
vaccin
trial
first
day
infect
neutral
antibodi
titer
often
low
howev
magnitud
nonneutr
antibodi
period
studi
hypothes
nonneutr
antibodi
earli
stage
infect
may
play
role
outcom
infect
detect
nonneutr
antibodi
use
elisa
plate
coat
splitvirion
inactiv
viru
vaccin
antigen
could
detect
neutral
nonneutr
antibodi
vaccin
protein
show
within
day
symptom
onset
significantli
higher
elisa
titer
found
patient
sever
diseas
mild
diseas
signific
differ
mn
titer
elisamn
titer
ratio
surrog
marker
amount
nonneutr
antibodi
higher
patient
sever
diseas
mild
diseas
patient
requir
ppv
repres
sever
respiratori
diseas
higher
elisa
titer
requir
ppv
result
studi
suggest
exagger
nonneutr
antibodi
respons
earli
stage
infect
associ
sever
diseas
nonneutr
antibodi
present
patient
earli
stage
infect
like
preexist
result
secondari
heterotyp
antibodi
respons
conserv
epitop
may
found
outsid
receptor
bind
pocket
ha
highli
conserv
nucleoprotein
matrix
protein
polymeras
protein
even
less
conserv
ns
protein
earli
igg
respons
happen
within
day
infect
immun
prime
previou
exposur
similar
viral
epitop
elisa
use
splitvirion
inactiv
vaccin
coat
antigen
contain
mainli
ha
also
protein
viru
includ
neuraminidas
matrix
protein
nucleoprotein
matrix
protein
nucleoprotein
conserv
amino
acid
sequenc
therefor
antibodi
protein
prior
season
influenza
viru
infect
vaccin
could
induc
upon
infect
viru
memori
b
cell
prolifer
rapidli
gener
larg
amount
highavid
nonneutr
antibodi
especi
patient
sever
diseas
consist
observ
number
peripher
blood
b
cell
higher
patient
sever
diseas
mild
diseas
earli
stage
infect
nonneutr
antibodi
influenza
viru
either
protect
neutral
nonprotect
detriment
effect
antibodi
ectodomain
nucleoprotein
shown
protect
anim
model
hand
antibodi
shown
delay
viral
clearanc
consist
previou
find
delay
viral
clearanc
rather
high
initi
viral
load
respiratori
tract
associ
sever
diseas
antibodi
detect
patient
influenza
viru
infect
function
signific
antibodi
unknown
potenti
effect
nonneutr
antibodi
includ
activ
complement
cascad
antibodydepend
cellular
cytotox
protect
detriment
excess
proinflammatori
besid
uncertainti
effect
clinic
outcom
avid
nonneutr
antibodi
complement
activ
antibodydepend
cytotox
also
unknown
effect
turn
detriment
conceiv
nonneutr
antibodi
high
avid
would
produc
damag
patient
antibodi
low
avid
though
notion
prior
season
influenza
vaccin
associ
wors
outcom
patient
subsequ
viru
infect
disput
nonneutr
antibodi
may
play
role
inde
case
detriment
effect
nonneutr
antibodi
specul
associ
poor
outcom
dengu
viru
respiratori
syncyti
viru
measl
viru
infect
via
antibodydepend
enhanc
though
laboratori
phenomenon
antibodydepend
enhanc
also
shown
influenza
viru
clinic
studi
ever
perform
ascertain
link
proor
antiinflammatori
effect
nonneutr
antibodi
pathogenesi
outcom
influenza
investig
antibodi
avid
assess
current
studi
compar
elisa
od
valu
without
urea
dissoci
agent
disrupt
interact
antibodi
coat
antigen
antibodi
bind
antigen
weakli
addit
urea
disrupt
bind
result
lower
od
valu
shown
higher
antibodi
avid
independ
associ
sever
diseas
consist
find
patient
sever
diseas
higher
level
secondari
antibodi
product
presum
memori
b
cell
find
appear
contradict
studi
monsalvo
et
al
show
patient
sever
viru
infect
lower
antibodi
avid
mild
diseas
sever
group
also
examin
relationship
age
antibodi
avid
patient
natur
infect
shown
antibodi
avid
higher
older
younger
age
group
antibodi
respons
influenza
vaccin
one
studi
show
higher
antibodi
avid
elderli
younger
vaccin
recipi
anoth
studi
find
differ
studi
find
correl
age
antibodi
avid
sever
import
differ
studi
may
explain
discrep
result
first
examin
serum
antibodi
present
shortli
natur
infect
probabl
differ
antibodi
aris
convalesc
phase
natur
infect
vaccin
second
use
splitvirion
influenza
vaccin
contain
ha
viral
protein
studi
use
pure
recombin
ha
without
viral
protein
may
differ
avid
antibodi
direct
ha
viral
protein
final
sampl
bia
may
occur
sever
case
patient
die
earli
sera
could
collect
convalesc
phase
studi
employ
splitvirion
inactiv
vaccin
approach
sever
advantag
use
recombin
antigen
first
use
vaccin
coat
antigen
could
detect
sum
wide
rang
igg
differ
viral
compon
instead
limit
igg
respons
specif
particular
protein
sinc
demonstr
antibodi
may
synergist
effect
studi
deem
relev
examin
antibodi
respons
rang
differ
viral
protein
instead
antibodi
respons
singl
viral
protein
second
recombin
protein
may
assum
alter
conform
conformationdepend
antibodi
may
recogn
alter
antigen
structur
use
vaccin
also
differ
use
inactiv
viru
zonal
centrifug
remov
nonvir
host
materi
may
lead
nonspecif
reaction
sever
limit
studi
test
antibodi
titer
serum
sampl
collect
day
day
symptom
onset
patient
attend
hospit
earli
stage
ill
except
ha
exact
quantiti
protein
present
batch
vaccin
known
howev
use
batch
vaccin
across
experi
ensur
consist
antigen
content
anoth
limit
assay
high
elisa
titer
may
relat
antibodi
could
neutral
viru
vivo
could
detect
current
mn
assay
final
although
high
elisa
titer
like
relat
rapid
product
nonneutr
antibodi
target
conserv
epitop
know
quantiti
preexist
antibodi
preinfect
serum
sampl
avail
studi
first
look
earli
antibodi
respons
neutral
nonneutr
antibodi
current
vaccin
compon
associ
antibodi
patient
outcom
excess
nonneutr
antibodi
respons
earli
infect
may
contribut
dysregul
inflamm
sever
infect
import
even
hi
titer
consid
protect
titer
reflect
mainli
neutral
antibodi
respons
vaccin
studi
associ
protect
efficaci
expos
popul
moreov
vaccin
patient
high
hi
titer
develop
diseas
exposur
influenza
viru
protect
therefor
absolut
overcom
larger
dose
viru
viru
enter
cell
viral
life
cycl
start
everi
infect
cell
produc
million
infecti
virion
easili
overcom
neutral
antibodi
interstiti
fluid
infect
adjac
cell
far
away
balanc
occur
dilut
viru
neutral
effect
antibodi
thu
anatom
site
viral
load
control
initi
innat
immun
respons
concomit
innat
inflammatori
respons
subsequ
mount
adapt
immun
respons
nonneutr
crossreact
antibodi
may
fuel
inflammatori
damag
signific
issu
elderli
sever
comorbid
whose
respiratori
reserv
margin
tissu
regen
power
poor
addit
inflammatori
cytokin
spill
circul
may
precipit
acut
catastroph
stroke
heart
attack
studi
conduct
ascertain
role
nonneutr
antibodi
pathogenesi
sever
influenza
